BioCentury
ARTICLE | Clinical News

Trabodenoson: Ph III MATrX-1 data

January 6, 2017 9:34 PM UTC

Top-line data from the double-blind, U.S. Phase III MATrX-1 trial in 303 patients with primary open-angle glaucoma or ocular hypertension showed that once-daily 3% and 6% and twice-daily 4.5% topical trabodenoson for 3 months all missed the primary endpoint of reducing mean IOP from baseline at each of 4 time points on days 28, 42 and 84 vs. placebo. IOP was measured at 8 AM, 10 AM, 12 PM and 4 PM. Inotek said that no dose of trabodenoson significantly reduced IOP compared to placebo at any of the 8 AM time points and that an "unexpectedly stronger placebo response" of 2-3 mmHg greater than that observed in a Phase II trial was observed...

BCIQ Company Profiles

Inotek Pharmaceuticals Corp.

BCIQ Target Profiles

Adenosine A1 receptor (ADORA1)